Certain TAAs are restricted to one or a few cancer types, such as the “mutated TAA” (BCR-ABL fusion, B-raf, k-ras, N-ras, p53, etc.), or the “differentiation TAA” (Melan-A/MART1, gp100, CEA, PSA, etc.), whereas others are shared between a wide range of cancers, such as the “shared tumor-specific TAA” (MAGE, NYESO-1, SSX, etc.)or the “overexpressed TAA” (HER-2/Neu, p53, Telomerase, MUC1, etc.)(http://www.archive.cancerimmunity.org/peptidedatabase/Tcellepitopes.htm). This evidence concerns the gene MLANA and neoplasm.